Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2-octyl cyanoacrylate is a long-chain cyanoacrylate ester used primarily as a topical tissue adhesive for the closure of surgical incisions and traumatic lacerations. Developed by Ethicon (a subsidiary of Johnson & Johnson) and marketed under the brand name Dermabond, it polymerizes in an exothermic reaction when exposed to moisture, creating a flexible, waterproof bridge that holds wound edges in apposition while providing a microbial barrier. Beyond surface wound care, it is utilized in interventional radiology and gastroenterology as a liquid embolic agent. In procedures such as percutaneous transhepatic variceal embolization (PTVE), it is injected into variceal veins where it rapidly solidifies upon contact with blood, inducing thrombosis and effectively managing gastroesophageal variceal bleeding in patients with portal hypertension and liver cirrhosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-octyl cyanoacrylate.